Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | RGS12 | O14924 | 1/20 | 0.70 |
| ▸ | NPC1 | O15118 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | RECQL | P46063 | 1/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.61 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3468337 | 1.00 | KDM4E (0.70) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7544499 | 1.00 | KDM4E (0.70) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7352888 | 1.00 | KDM4E (0.70) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7285741 | 1.00 | KDM4E (0.70) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7296911 | 1.00 | KDM4E (0.70) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4179085 | 1.00 | KDM4E (0.70) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL17275126 | 1.00 | KDM4E (0.70) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1162502 | 1.00 | KDM4E (0.70) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3468673 | 1.00 | KDM4E (0.70) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1703575 | 1.00 | KDM4E (0.70) | KDM4EALDH1A1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0662834-A4 | NOVEL EPOXIDE-CONTAINING COMPOUNDS. | CELL THERAPEUTICS INC (US) | 1996-04-17 | — | — | EP | claimed |
| EP-0662834-A1 | NOVEL EPOXIDE-CONTAINING COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1995-07-19 | — | — | EP | claimed |
| WO-1994006431-A1 | NOVEL EPOXIDE-CONTAINING COMPOUNDS | CELL THERAPEUTICS, INC. (US) | 1994-03-31 | — | — | WO | claimed |
| US-12624044-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| CN-118255685-A | Tricyclic compound, pharmaceutical composition and application thereof | 珂阑(上海)医药科技有限公司 | 2024-06-28 | — | — | CN | disclosed |
| US-11833208-B2 | PLK1 selective degradation inducing compound | UPPTHERA, INC. (KR) | 2023-12-05 | — | — | US | disclosed |
| US-20230372498-A1 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | UPPTHERA (KR) | 2023-11-23 | — | — | US | disclosed |
| US-20230348362-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230348362-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2023-11-02 | — | — | US | disclosed |
| CN-116444494-A | Compound for targeted degradation of BUB1B and BUB1 protein, and preparation method and application thereof | 浙江大学 | 2023-07-18 | — | — | CN | disclosed |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
| EP-1755684-A2 | ALBUMIN-BINDING CONJUGATES COMPRISING A FATTY ACID AND PEG | Celltech R&D Limited (GB) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005117984-A2 | ALBUMIN-BINDING CONJUGATES COMPRISING A FATTY ACID AND PEG | CELLTECH R & D LIMITED (GB) | 2005-12-15 | — | — | WO | disclosed |
| WO-2002016314-A1 | SUBSTITUTED POLYAMINE COMPOUNDS | H. LUNDBECK A/S (DK) | 2002-02-28 | — | — | WO | disclosed |
| US-5652247-A | VASOPRESSIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD (JP) | 1997-07-29 | — | — | US | disclosed |
| US-5436254-A | Vaopressin antagonists | OTSUKA PHARMACEUTICAL COMPANY, LTD. (JP) | 1995-07-25 | — | — | US | disclosed |
| EP-0602209-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-06-22 | — | — | EP | disclosed |
| EP-0382185-B1 | Carbostyril derivatives | OTSUKA PHARMA CO LTD (JP) | 1994-06-15 | — | — | EP | disclosed |
| WO-1994001113-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1994-01-20 | — | — | WO | disclosed |
| US-5225402-A | Vasopressin antagonist, vasodilation, hypotensive, diuretics and anticoagulants | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372498-A1 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | KDM4E 1207/4885ALDH1A1 3592/4885MEN1 1845/4885 |
| US-20230348362-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | CETP, NPC1, LCAT | KDM4E 3784/4885ALDH1A1 4264/4885MEN1 1909/4885 |
| US-12624044-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCC1, SMARCA2 | KDM4E 315/4885ALDH1A1 3543/4885MEN1 1936/4885 |
| US-11833208-B2 | PLK1 selective degradation inducing compound | PLK1, BUB1B, BUB1 | KDM4E 1207/4885ALDH1A1 3592/4885MEN1 1845/4885 |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | KDM4E 624/4885ALDH1A1 3736/4885MEN1 1348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.